AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
July 10, 2017
12:00PM- 5:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Dan Lindell
Berkely McMurray
Cindy Komar
Stephen Chakmakian
Kathleen Bryant
Lydia Nesemann
Gloria Abril
Shawn McMahon
Joanna Kowalik
Suzanne Campbell
Robert Marotz
Mohamed Ramadan
Otto Uhrik

AHCCCS Staff:
Sara Salek
Suzi Berman
Robin Davis
Lauren Prole

Magellan Medicaid Admin:
Richard Pope
Doug Brown
Christopher Andrews

Members Absent:
James Hargrave
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:05 PM and welcomed committee members, staff, and guest presenters.
   a. Dr. Salek requested that committee members interested in continuing on the committee submit their names via email.
   b. P&T Minutes from April 13, 2017 were reviewed.
      i. Motion made by Suzanne Campbell to approve the meeting minutes.
      ii. Motion seconded by Joanna Kowalik
      iii. A majority of the committee members voted in favor of approving the minutes
      iv. No committee members opposed
      v. 1 committee member abstained.

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEWS

Supplemental Rebate Class Review:

1. Oral Atypical (Second Generation) Antipsychotics
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Rexulti: Kristin Pareja, Otsuka
   c. Public Testimony:
      i. Kristina Sabetta, Mental Health America of Arizona

2. Long-Acting Injectable Antipsychotics
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Abilify Maintena: Kristin Pareja, Otsuka
      ii. Aristada: Kenneth Berry, Alkermes
      iii. Invega Sustenna: Steve Zona, Janssen Scientific Affairs
      iv. Trinza: Steve Zona, Janssen Scientific Affairs
   c. Public Testimony:
      i. Carol Olson MD, Maricopa Integrated Health System
      ii. Thomas Gazda, MD
      iii. Charles Goldstein

3. Stimulants & Related Agents
a. Clinical review: Rick Pope: Provider Synergies  
b. Pharma Testimony:  
   i. Adzenys XR-ODT: George Kehner, Neos Therapeutics  
   ii. Aptensio XR: Christina Heiner, Rhodes Pharmaceuticals  
   iii. Dyanavel XR: Zulma Schlossberg, Tris Pharma  
   iv. Quillivant XR: Steve Fuchs, Pfizer  
   v. Quillichew: Steve Fuchs, Pfizer  
c. Public Testimony: None

4. Pancreatic Enzymes  
a. Clinical review: Rick Pope: Provider Synergies  
b. Pharma Testimony: None  
c. Public Testimony: None

5. Anticoagulants  
a. Clinical review: Rick Pope: Provider Synergies  
b. Pharma Testimony:  
   i. Eliquis: Jon Glover, Pfizer  
   ii. Xarelto: Steve Zona, Janssen Scientific Affairs  
c. Public Testimony: None

Non-Supplemental Rebate Class Review:  
1. Hemophilia Factor  
a. Clinical review: Rick Pope: Provider Synergies  
b. Pharma Testimony:  
   i. Alprolix: Alex Bitting, Bioverativ  
   ii. Eloctate: Alex Bitting, Bioverativ  
   iii. Kogenate FS: Trina Ballard, Bayer  
   iv. Kovaltry FVIII: Trina Ballard, Bayer  
c. Public Testimony:  
   i. Danielle Nance, Arizona Bleeding Disorders Health and Wellness Center  
   ii. Andrew Blacklidge, Arizona Hemophilia Association  
   iii. Esteban Gomez, Phoenix Children’s Hospital Hemophilia Center  
   iv. Josue Terazon  
   v. Tyler Lipinski  
   vi. David Cabrera  
   vii. Tony Hernandez  
   viii. Marco Bojorges  
   ix. Brent Davila
Executive Session – Closed to the Public

Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes.

1. Hypoglycemics, Insulin & Related Agents (tabled from April 2017 meeting)
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Continue current preferred products and add:
         1. Novolog Vials, Cartridges, & Pens
         2. Novolog Mix Vials, & Pens

2. Hemophilia Factor Products
   a. A majority of committee members voted in favor on the below recommendations. No committee members opposed. One committee member abstained.
      i. Continue current management
         1. All factor available via prior authorization
         2. Form a Hemophilia subcommittee for further review and recommendation

3. Oral Atypical (Second Generation) Antipsychotics
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Aripiprazole ODT, solution & tablets
      ii. Clozapine ODT & oral tablets
      iii. Latuda
      iv. Olanzapine ODT & oral tablets
      v. Quetiapine tablets
      vi. Risperidone ODT, solution & oral tablets
      vii. Saphris
      viii. Ziprasidone tablets

4. Long-Acting Injectable Agents
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Abilify Maintena
      ii. Aristada
      iii. Invega Sustenna
iv. Invega Trinza
v. Risperdal Consta

5. Stimulants and related agents
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Adderall XR
      ii. Amphetamine salt combination
      iii. Aptensio XR (added)
      iv. Daytrana
      v. Dextroamphetamine capsule ER
      vi. Dextroamphetamine tablet
      vii. Focalin
      viii. Focalin XR
      ix. Guanfacine ER
      x. Kapvay
      xi. Methylphenidate
      xii. Methylphenidate CD (added)
      xiii. Methylphenidate ER (generic Concerta)
      xiv. Methylphenidate ER (generic Ritalin LA)
      xvi. Quillichew ER
      xvii. Quillivant XR
      xviii. Ritalin LA 10mg capsule
      xix. Strattera
      xx. Vyvanse Capsule

6. Pancreatic Enzymes
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Creon
      ii. Zenpep

7. Anticoagulant- Oral
a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
   i. Eliquis
   ii. Pradaxa
   iii. Xarelto
   iv. Xarelto dose pack (added)
   v. Warfarin

8. Anticoagulants- Injectable
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Enoxaparin Syringes and Vials – are preferred (added)
      ii. Lovenox Syringes and/or Vials – as non preferred

AHCCCS Drug Lists Alignment for Behavioral health Drugs & Vote- Michelle Cavner, Pharmacy Director, MMIC

1. Proposed recommendation is to bring parity and alignment across both AHCCCS drug lists as well as across RBHA plans.
   a. Prior Authorization requirements
   b. Quantity Limits
   c. Age
   d. Addition of drugs not listed
   e. This recommendation will be sent out to the committee members for vote via email.

BIOSIMILAR UPDATE

1. Inflectra (infliximab-dyyb)
2. Renflexis (Infliximab-abda)
3. The recommendation is to continue the use of Remicade as the preferred infliximab product because it is the most cost effective infliximab product to the State.

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SUZI BERMAN

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
a) Austedo (Deutertrabenazine)
   i) Recommendation is to not add Austedo to the AHCCCS drug list due to the lack of evidence to support the clinical efficacy.
      (1) All committee members voted in favor of the recommendations.
      (2) No committee members voted against the recommendations.
      (3) No committee member abstained.

b) Dupixent (Dupiluma)
   i) Recommendation is to not add Dupixent to the AHCCCS Drug List because the use of Dupixent is indicated when the atopic dermatitis is not controlled by topical steroids. There are many steroids and other products available for the treatment of atopic dermatitis on the AHCCCS Drug List.
      (1) All committee members voted in favor of the recommendations.
      (2) No committee members voted against the recommendations.
      (3) No committee member abstained.

c) Rhofade (Oxymetazoline HCL 1% Cream)
   i) Recommendation is to not add this medication to the AHCCCS Drug List because there are many other topical medications on the AHCCCS Drug List, which are efficacious and more cost effective.
      (1) All committee members voted in favor of the recommendations.
      (2) No committee members voted against the recommendations.
      (3) No committee member abstained.

d) Symproic (Naldemedine)
   i) Recommendation is to not add Symproic to the AHCCCS Drug List because there are many alternatives available that are more cost effective to treat constipation.
      (1) All committee members voted in favor of the recommendations.
      (2) No committee members voted against the recommendations.
      (3) No committee member abstained.

e) Xadago (Safinamide)
   i) Recommendation is to not add Xadago to the AHCCCS Drug List because the primary endpoint outcomes of Xadago were very similar to placebo.
      (1) All committee members voted in favor of the recommendations.
      (2) No committee members voted against the recommendations.
(3) No committee member abstained.

f) Ingrezza (Valbenazine)
   i) Recommendation is to not add Ingrezza to the AHCCCS Behavioral Health Drug List because there is minimal benefit as evidenced by the endpoints of the study.
   (1) All committee members voted in favor of the recommendations.
   (2) No committee members voted against the recommendations.
   (3) No committee member abstained.

g) Emflaza (Deflazacort)
   i) Recommendation is to not add Emflaza to the AHCCCS Drug List.
   (1) All committee members voted in favor of the recommendations.
   (2) No committee members voted against the recommendations.
   (3) No committee member abstained.

NEXT MEETING DATES

2017 Meeting Dates: Thursday October 12, 2017

ADJOURNMENT

The meeting adjourned at 5:
Minutes recorded by Robin Davis

___Suzi Berman RPh___________________________ October 12, 2017
Suzi Berman, RPh Date
Director of Pharmacy Services